JP2020536896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536896A5 JP2020536896A5 JP2020520127A JP2020520127A JP2020536896A5 JP 2020536896 A5 JP2020536896 A5 JP 2020536896A5 JP 2020520127 A JP2020520127 A JP 2020520127A JP 2020520127 A JP2020520127 A JP 2020520127A JP 2020536896 A5 JP2020536896 A5 JP 2020536896A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- disorder
- composition
- systemic inflammatory
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000027866 inflammatory disease Diseases 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000009885 systemic effect Effects 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 6
- 208000020832 chronic kidney disease Diseases 0.000 claims description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 206010011793 Cystitis haemorrhagic Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 201000002802 hemorrhagic cystitis Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 229910052717 sulfur Inorganic materials 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 239000001301 oxygen Chemical group 0.000 description 17
- 239000011593 sulfur Chemical group 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 14
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 229910052805 deuterium Inorganic materials 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 208000002205 allergic conjunctivitis Diseases 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000004431 deuterium atom Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- NOFRQDXKZDAYGB-UHFFFAOYSA-N CC(C)(c1nc(cccc2)c2cc1N)O Chemical compound CC(C)(c1nc(cccc2)c2cc1N)O NOFRQDXKZDAYGB-UHFFFAOYSA-N 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012692 Diabetic uveitis Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000010794 infectious panuveitis Diseases 0.000 description 1
- 208000010760 infectious posterior uveitis Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000024965 non-infectious anterior uveitis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023107073A JP2023115307A (ja) | 2017-10-10 | 2023-06-29 | 炎症性障害の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570389P | 2017-10-10 | 2017-10-10 | |
| US62/570,389 | 2017-10-10 | ||
| US201862644263P | 2018-03-16 | 2018-03-16 | |
| US62/644,263 | 2018-03-16 | ||
| PCT/US2018/055310 WO2019075136A1 (en) | 2017-10-10 | 2018-10-10 | TREATMENT OF INFLAMMATORY DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023107073A Division JP2023115307A (ja) | 2017-10-10 | 2023-06-29 | 炎症性障害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536896A JP2020536896A (ja) | 2020-12-17 |
| JP2020536896A5 true JP2020536896A5 (https=) | 2021-11-18 |
| JP7311162B2 JP7311162B2 (ja) | 2023-07-19 |
Family
ID=65992347
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520127A Active JP7311162B2 (ja) | 2017-10-10 | 2018-10-10 | 炎症性障害の処置 |
| JP2023107073A Pending JP2023115307A (ja) | 2017-10-10 | 2023-06-29 | 炎症性障害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023107073A Pending JP2023115307A (ja) | 2017-10-10 | 2023-06-29 | 炎症性障害の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11040039B2 (https=) |
| EP (1) | EP3694500A4 (https=) |
| JP (2) | JP7311162B2 (https=) |
| CN (1) | CN111356451A (https=) |
| AU (1) | AU2018348174A1 (https=) |
| CA (1) | CA3077362A1 (https=) |
| IL (1) | IL273693A (https=) |
| MX (1) | MX2020003425A (https=) |
| WO (1) | WO2019075136A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US10550085B2 (en) | 2015-08-21 | 2020-02-04 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3856478A4 (en) | 2018-09-25 | 2022-06-08 | Aldeyra Therapeutics, Inc. | FORMULATIONS FOR THE TREATMENT OF DRY EYE |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2021007140A (es) * | 2018-12-18 | 2021-11-03 | Medshine Discovery Inc | Compuesto para usarse en enfermedades de la retina. |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| US20230149383A1 (en) * | 2020-04-13 | 2023-05-18 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
| WO2021222366A1 (en) * | 2020-04-28 | 2021-11-04 | Kymera Therapeutics, Inc. | Irak inhibitors and uses thereof |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN115702144A (zh) * | 2020-06-17 | 2023-02-14 | 南京明德新药研发有限公司 | 氨基吡啶类化合物 |
| US11753377B2 (en) * | 2020-06-17 | 2023-09-12 | Zhuhai United Laboratories Co., Ltd. | Crystal form of 2-methyl-2-propanol and amino-substituted aryl compound |
| MX2023003583A (es) * | 2020-09-28 | 2023-04-04 | Zhuhai United Laboratories Co Ltd | Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo. |
| EP4273150A4 (en) * | 2020-12-29 | 2024-04-24 | The National Institutes of Pharmaceutical R&D Co., Ltd | TRICYCLIC COMPOUND AND PRODUCTION PROCESS THEREOF AND MEDICAL USE THEREOF |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| WO2022232110A1 (en) * | 2021-04-26 | 2022-11-03 | Jem Therapeutics Pbc | Method of treatment for autophagy diseases by administration of dexibuprofen and use of dexibuprofen for preparation of a medicament for same |
| AU2022303386A1 (en) * | 2021-07-02 | 2023-12-14 | Aldeyra Therapeutics, Inc. | Heterocyclic aldehyde trapping compounds and uses thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| KR20250111213A (ko) * | 2022-11-26 | 2025-07-22 | 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 | 피리딘 페닐 화합물을 포함하는 안과용 제형, 이의 제조 방법, 및 이의 용도 |
| CN120424003A (zh) * | 2024-02-02 | 2025-08-05 | 深圳新锐基因科技有限公司 | 一种基于ai设计的活性醛类物质抑制剂及其应用 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| SU50906A1 (ru) | 1935-12-20 | 1936-11-30 | А.И. Бурляев | Веретено дл пр дильных машин |
| GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| JPS6192592A (ja) | 1984-10-12 | 1986-05-10 | Norin Suisansyo Shokuhin Sogo Kenkyusho | 分岐サイクロデキストリンの製造方法 |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| NZ225045A (en) | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| BR9106193A (pt) | 1990-10-22 | 1993-03-23 | Bausch & Lomb | Metodo e composicao para limpar lentes de contato |
| AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| TW401300B (en) | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| US5767109A (en) | 1993-10-20 | 1998-06-16 | Sanchez; Robert A. | Complexing urushiols |
| US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
| JP3297969B2 (ja) | 1994-12-26 | 2002-07-02 | ライオン株式会社 | 点眼剤 |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| JP3736916B2 (ja) | 1996-02-19 | 2006-01-18 | 株式会社サンコンタクトレンズ | 含水性ソフトコンタクトレンズの消毒用組成物とその用途 |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| KR20000029694A (ko) | 1996-08-01 | 2000-05-25 | 케네쓰 엘. 로에르트셔 | 살진균활성을갖는4-치환된퀴놀린유도체 |
| BR9710808A (pt) * | 1996-08-06 | 1999-08-17 | Pfizer | Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos |
| US6191127B1 (en) | 1997-05-02 | 2001-02-20 | Schering Aktiengesellschaft | Substituted heterocycles and their use in medicaments |
| GB2327672A (en) | 1997-07-23 | 1999-02-03 | Merck & Co Inc | 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine |
| US6245769B1 (en) * | 1997-09-02 | 2001-06-12 | Dupont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders |
| WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6515010B1 (en) | 1999-11-15 | 2003-02-04 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
| AU1735001A (en) | 1999-12-10 | 2001-06-18 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| JP4748289B2 (ja) | 2000-06-23 | 2011-08-17 | ライオン株式会社 | 点眼剤、眼科用組成物及び吸着抑制方法 |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20040198828A1 (en) | 2003-01-17 | 2004-10-07 | Abelson Mark B. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
| EP3326623A1 (en) | 2003-03-14 | 2018-05-30 | University of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
| EP1621199B8 (en) | 2003-04-18 | 2011-01-19 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| JP2005132834A (ja) | 2003-10-09 | 2005-05-26 | Kyowa Hakko Kogyo Co Ltd | キノリン誘導体 |
| EP1679308B1 (en) | 2003-10-15 | 2013-07-24 | Ube Industries, Ltd. | Novel indazole derivative |
| CA2543644A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| CA2546042A1 (en) | 2003-11-20 | 2005-06-09 | Othera Pharmaceuticals, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| US20080176952A1 (en) | 2004-02-17 | 2008-07-24 | Rando Robert R | Management of Ophthalmologic Disorders, Including Macular Degeneration |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| JP2006008568A (ja) | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | ＩｇＥ抗体抑制剤および食品 |
| WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
| US20070287716A1 (en) | 2004-10-28 | 2007-12-13 | Hu Essa H | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors |
| EP1844768A1 (en) | 2005-01-19 | 2007-10-17 | Dainippon Sumitomo Pharma Co., Ltd. | Aromatic sulfone compound as aldosterone receptor modulator |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| EP1893174A2 (en) | 2005-05-10 | 2008-03-05 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| EP1967186B1 (en) | 2005-12-27 | 2015-03-11 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| US7842312B2 (en) | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
| US20070297981A1 (en) | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| JP4466875B2 (ja) | 2006-04-05 | 2010-05-26 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
| CN101534826A (zh) | 2006-04-14 | 2009-09-16 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性（amd）的方法 |
| JP5194218B2 (ja) | 2006-06-05 | 2013-05-08 | 株式会社メニコンネクト | 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ |
| JP2009544631A (ja) | 2006-07-25 | 2009-12-17 | エンビボ ファーマシューティカルズ インコーポレイテッド | キノリン誘導体 |
| CA2660703A1 (en) | 2006-08-14 | 2008-02-21 | Schering Corporation | Salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide |
| US20080069878A1 (en) | 2006-08-31 | 2008-03-20 | Gopi Venkatesh | Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs |
| US8158609B1 (en) | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
| US20080241256A1 (en) | 2007-03-30 | 2008-10-02 | Liisa Kuhn | Targeted active agent delivery system based on calcium phosphate nanoparticles |
| US20090118503A1 (en) | 2007-06-20 | 2009-05-07 | Kevin Sprott | Faah inhibitors |
| CN103553945B (zh) | 2007-10-05 | 2015-01-07 | 奥克塞拉有限公司 | 用于治疗疾病的烷氧基化合物 |
| WO2009102418A1 (en) | 2008-02-11 | 2009-08-20 | University Of Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
| AU2009282076A1 (en) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
| JP5773877B2 (ja) | 2008-10-22 | 2015-09-02 | アキュセラ インコーポレイテッド | 眼の疾患及び障害を治療する化合物 |
| JP2012508215A (ja) | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | 有機化合物 |
| CA2754996A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
| WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
| MX2011013061A (es) | 2009-06-05 | 2012-02-28 | Aciex Therapeutics Inc | Formulaciones oftalmicas de fluticasona y metodos de uso. |
| WO2010148351A1 (en) | 2009-06-18 | 2010-12-23 | Cylene Pharmaceuticals, Inc. | Rhodanines and related heterocycles as kinase inhibitors |
| WO2011008202A1 (en) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| TWI492769B (zh) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| JPWO2011078204A1 (ja) | 2009-12-24 | 2013-05-09 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| WO2011116066A1 (en) | 2010-03-17 | 2011-09-22 | Concert Pharmaceuticals, Inc. | Derivatives of dimethylcurcumin |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| EP3208263A1 (en) | 2011-01-12 | 2017-08-23 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| US10463687B2 (en) | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
| US9302013B2 (en) | 2011-01-31 | 2016-04-05 | Termira Ab | Active principle for mitigating undesired medical conditions |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| HK1202064A1 (en) | 2011-10-13 | 2015-09-18 | 托马斯．盖德克 | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions |
| US20130190500A1 (en) | 2011-12-12 | 2013-07-25 | Neuron Systems, Inc. | Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| MX367879B (es) | 2012-08-01 | 2019-09-10 | Lewis And Clark Pharmaceuticals Inc | N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a. |
| MX373894B (es) | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| AU2013361314A1 (en) | 2012-12-20 | 2015-07-02 | Aldeyra Therapeutics, Inc. | Peri-carbinols |
| NZ709620A (en) | 2013-01-23 | 2020-07-31 | Semnur Pharmaceuticals Inc | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
| CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US10111862B2 (en) | 2013-01-25 | 2018-10-30 | Aldeyra Therapeutics, Inc. | Traps in the treatment of macular degeneration |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| US9713330B1 (en) | 2013-03-15 | 2017-07-25 | Deuteria Agrochemicals, Llc | Deuterium-enriched aldehydes |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| US10272106B2 (en) | 2014-06-04 | 2019-04-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
| WO2015198350A1 (en) | 2014-06-25 | 2015-12-30 | Synergia Bio Sciences Private Limited | A pharmaceutical oil-in-water nano-emulsion |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| NO2721710T3 (https=) * | 2014-08-21 | 2018-03-31 | ||
| AU2015312134A1 (en) | 2014-09-02 | 2017-03-23 | Bhupinder Singh | Deuterated or a non-deuterated molecule and pharmaceutical formulations |
| TW201628622A (zh) | 2014-11-17 | 2016-08-16 | 製藥公司 | Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合 |
| US10363231B2 (en) | 2014-11-24 | 2019-07-30 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| CN113307805A (zh) | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| KR20180073553A (ko) | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | 알데히드 접합체 및 이의 용도 |
| US10550085B2 (en) | 2015-08-21 | 2020-02-04 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| KR20180116416A (ko) | 2016-02-28 | 2018-10-24 | 알데이라 테라퓨틱스, 아이엔씨. | 사이클로덱스트린으로의 알레르기성 안질환의 치료 |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| EP3463277A4 (en) | 2016-06-06 | 2020-01-01 | GDD Therapeutics, LLC | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS THEREFOR AND USES THEREOF |
| WO2018039192A1 (en) * | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
| CA3032609A1 (en) | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and methods of use thereof |
| US11510931B2 (en) | 2016-09-28 | 2022-11-29 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| CA3054811A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| WO2020018498A1 (en) | 2018-07-16 | 2020-01-23 | Aldeyra Therapeutics, Inc. | Cyclodextrin formulations |
| WO2020028820A1 (en) * | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| AU2019319740A1 (en) | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3856478A4 (en) | 2018-09-25 | 2022-06-08 | Aldeyra Therapeutics, Inc. | FORMULATIONS FOR THE TREATMENT OF DRY EYE |
| WO2020072621A1 (en) | 2018-10-02 | 2020-04-09 | Aldeyra Therapeutics, Inc. | Contact lens solutions and kits |
| WO2020118045A1 (en) | 2018-12-05 | 2020-06-11 | Aldeyra Therapeutics, Inc. | Injectable formulations |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US20230131929A1 (en) | 2020-03-24 | 2023-04-27 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating respiratory disorders and viral infections |
| US20230149383A1 (en) | 2020-04-13 | 2023-05-18 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2021248031A1 (en) | 2020-06-04 | 2021-12-09 | Aldeyra Therapeutics, Inc. | Dry eye disease biomarkers and their use for treatment |
| WO2022150580A1 (en) | 2021-01-07 | 2022-07-14 | Aldeyra Therapeutics, Inc. | Treatment of dry eye disease |
| US20220211691A1 (en) | 2021-01-07 | 2022-07-07 | Aldeyra Therapeutics, Inc. | Treatment of dry eye disease |
-
2018
- 2018-10-10 WO PCT/US2018/055310 patent/WO2019075136A1/en not_active Ceased
- 2018-10-10 EP EP18865612.8A patent/EP3694500A4/en not_active Withdrawn
- 2018-10-10 CN CN201880073697.1A patent/CN111356451A/zh active Pending
- 2018-10-10 MX MX2020003425A patent/MX2020003425A/es unknown
- 2018-10-10 US US16/157,069 patent/US11040039B2/en active Active
- 2018-10-10 AU AU2018348174A patent/AU2018348174A1/en not_active Abandoned
- 2018-10-10 JP JP2020520127A patent/JP7311162B2/ja active Active
- 2018-10-10 CA CA3077362A patent/CA3077362A1/en active Pending
-
2020
- 2020-03-30 IL IL273693A patent/IL273693A/en unknown
-
2021
- 2021-05-24 US US17/328,772 patent/US11583529B2/en active Active
-
2023
- 2023-01-03 US US18/092,758 patent/US20230248727A1/en not_active Abandoned
- 2023-05-26 US US18/202,694 patent/US20230293527A1/en not_active Abandoned
- 2023-06-29 JP JP2023107073A patent/JP2023115307A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536896A5 (https=) | ||
| SU1433412A3 (ru) | Способ получени 5- @ 4-(4-ацетил-3-окси-2-пропилфенокси)бутил @ -тетразола | |
| CN102348680B (zh) | 用于制备光学活性二胺衍生物的方法 | |
| JP2022003062A5 (https=) | ||
| CN1094490C (zh) | 作为血清素拮抗剂的喹诺－2(1h)－酮衍生物 | |
| JP2024529839A5 (https=) | ||
| RU2019107938A (ru) | Производное оксопиколинамида, способ его получения и его фармацевтическое применение | |
| JP2017533895A5 (https=) | ||
| WO2006019962B1 (en) | Compositions and methods for treatment of colitis | |
| JP2021523200A5 (https=) | ||
| JP2003532626A5 (https=) | ||
| WO2016035006A1 (en) | Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir | |
| JP2025509697A5 (https=) | ||
| RU2020112502A (ru) | Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона | |
| JP2020536082A5 (https=) | ||
| JP2023518411A5 (https=) | ||
| JP2005505595A5 (https=) | ||
| JP2022538299A5 (https=) | ||
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| JP2024536869A5 (https=) | ||
| JP2021522262A5 (https=) | ||
| JPH09216885A (ja) | Ｎ−［３−（３−シアノピラゾロ［１，５−ａ］ピリミジン−７−イル）フェニル］−Ｎ−エチル−アセトアミドの改良された製造方法 | |
| JP2022504607A5 (https=) | ||
| JP2005539045A5 (https=) | ||
| JP2015532289A5 (https=) |